Healing course of primate ulna segmental defects treated with osteogenic protein-1

被引:37
作者
Cook, SD
Salkeld, SL
Patron, LP
Sargent, MC
Rueger, DC
机构
[1] Tulane Univ, Sch Med, Dept Orthoped Surg, New Orleans, LA 70112 USA
[2] Stryker Biotech, Hopkinton, MA USA
关键词
bone induction; bone morphogenetic protein; healing; primate; segmental defect;
D O I
10.1080/08941930290085822
中图分类号
R61 [外科手术学];
学科分类号
摘要
Twelve African green monkeys were implanted with recombinant human osteogenic protein-1 (rhOP-1) placed on a bovine bone-derived Type I collagen carrier to characterize healing in an ulna segmental bone defect model at 1, 3, 12, and 20 weeks postoperative. Defect healing was evaluated by plain film radiography, computed tomography (CT), magnetic resonance imaging (MRI), bone mineral density (BMD), and histologic analysis. Radiographically, new bone formation was observed as early as 3 weeks postoperative. By 6 weeks, new bone was visible in five of six defects. Increased quantity and mineralization of the new bone were apparent by 12 weeks. Reformation of the medullary cavity with appearance of marrow elements was demonstrated by CT and MRI at 20 weeks. BMD studies revealed a significant increase in the presence of bone with time. Histology at 1 week demonstrated that the implant material was well contained in the defect, and a proliferation of cells occurred at the defect borders. At 3 weeks cell proliferation continued and cell phenotype differentiation was recognized. By 12 weeks substantially less residual carrier was found in the defects, and calcifying tissues with plump chondrocytes, osteoblasts, and immature woven bone were observed. Areas of lamellar and woven bone were identified at 12 weeks, with advanced remodeling and revascularization observed at 20 weeks. The use of osteoinductive implants may provide an alternative to autologous and allogeneic bone tissue in the therapeutic approach to bone defects and promotion of fusion by eliminating the donor site morbidity associated with autogenous bone and the decreased efficacy and potential for disease transmission associated with allogeneic bone.
引用
收藏
页码:69 / 79
页数:11
相关论文
共 23 条
[1]  
[Anonymous], 1988, Morbility and Mortality Weekly Report - Recommendations and Reports, V37, P597
[2]  
Cockin J., 1971, J BONE JOINT SURG BR, V53, P153
[3]   EFFECT OF RECOMBINANT HUMAN OSTEOGENIC PROTEIN-1 ON HEALING OF SEGMENTAL DEFECTS IN NONHUMAN-PRIMATES [J].
COOK, SD ;
WOLFE, MW ;
SALKELD, SL ;
RUEGER, DC .
JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME, 1995, 77A (05) :734-750
[4]  
COOK SD, 1994, CLIN ORTHOP RELAT R, P302
[5]   THE EFFECT OF RECOMBINANT HUMAN OSTEOGENIC PROTEIN-1 ON HEALING OF LARGE SEGMENTAL BONE DEFECTS [J].
COOK, SD ;
BAFFES, GC ;
WOLFE, MW ;
SAMPATH, TK ;
RUEGER, DC ;
WHITECLOUD, TS .
JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME, 1994, 76A (06) :827-838
[6]   BONE-GRAFT AND BONE-GRAFT SUBSTITUTES - A REVIEW OF CURRENT TECHNOLOGY AND APPLICATIONS [J].
DAMIEN, CJ ;
PARSONS, JR .
JOURNAL OF APPLIED BIOMATERIALS, 1991, 2 (03) :187-208
[7]   A COMPARATIVE STUDY OF THE HEALING PROCESS FOLLOWING DIFFERENT TYPES OF BONE TRANSPLANTATION [J].
HEIPLE, KG ;
CHASE, SW ;
HERNDON, CH .
JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME, 1963, 45 (08) :1593-1616
[8]  
HOROWITZ MC, 1991, BONE AND CARTILAGE ALLOGRAFTS : BIOLOGY AND CLINICAL APPLICATIONS, P85
[9]  
Key JA, 1934, J BONE JOINT SURG, V16, P176
[10]  
LUYTEN FP, 1989, J BIOL CHEM, V264, P13377